



**Maidstone and  
Tunbridge Wells**  
NHS Trust

Ref: FOI/GS/ID 7302

**Please reply to:**  
FOI Administrator  
Trust Management  
Maidstone Hospital  
Hermitage Lane  
Maidstone, Kent  
ME16 9QQ  
Email: [mtw-tr.foiadmin@nhs.net](mailto:mtw-tr.foiadmin@nhs.net)  
[www.mtw.nhs.uk](http://www.mtw.nhs.uk)

14 April 2022

## **Freedom of Information Act 2000**

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Head and Neck cancer (squamous cell carcinoma) and Urothelial cancer.

*You asked:*

*1. How many patients have been treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the following agents:*

- a. Carboplatin (monotherapy or in combination with 5-FU)*
- b. Cisplatin (monotherapy or in combination with 5-FU)*
- c. Cetuximab with/without chemotherapy*
- d. Cetuximab with radiotherapy*
- e. Pembrolizumab monotherapy*
- f. Pembrolizumab with chemotherapy*
- g. Nivolumab*
- h. Docetaxel (monotherapy or in combination with 5-FU)*
- i. Fluorouracil (5FU)*
- j. Radiotherapy only*
- k. Other*

*2. For the patients treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the therapies listed in the first question, please provide:*

- a. Total number of head and neck cancer patients*
- b. Number of locally advanced head and neck cancer patients*
- c. Number of recurrent and/or metastatic head and neck cancer patients*

*3. How many Urothelial cancer patients have been treated in the past 3 months with the following agents:*

- a. Atezolizumab*
- b. Carboplatin with Gemcitabine*
- c. Carboplatin single or in any other combination*
- d. Cisplatin with Gemcitabine*

- e. *Cisplatin single or in any other combination*
  - f. *Nivolumab*
  - g. *Pembrolizumab*
  - h. *Any other regimen including Paclitaxel*
  - i. *Any other chemotherapy regimen*
  - j. *Other active systemic anti-cancer therapy [please state]*
  - k. *Palliative care only*
4. *Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?*

Trust response:

1.

a. 9

b. 8

c. 2

d. 0

e. 4

f. 0

g. 7

h. 0

i. 0

j. 47

k. Not available

2.

a. 76

b. 33

c. 2

3.

a. 1

b. 5

c. 0

d. 3

e. 0

f. 0

g. 1

h. 0

i. 0

j. 1 Avelumab

k. Not available

4. The Trust does not have any ongoing trials for urothelial cancer.